Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Artif Intell Gastroenterol. Jun 28, 2021; 2(3): 69-76
Published online Jun 28, 2021. doi: 10.35712/aig.v2.i3.69
Artificial intelligence in gastrointestinal diseases
Shihori Tanabe, Edward J Perkins, Ryuichi Ono, Hiroki Sasaki
Shihori Tanabe, Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki 210-9501, Japan
Edward J Perkins, Environmental Laboratory, US Army Engineer Research and Development Center, Vicksburg, MS 3180, United States
Ryuichi Ono, Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki 210-9501, Japan
Hiroki Sasaki, Department of Clinical Genomics, Fundamental Innovative Oncology Core, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Author contributions: Tanabe S designed the outline and coordinated the writing of the paper, performed the majority of the writing and editing, and prepared the figure and table; Perkins EJ performed the editing; Ono R and Sasaki H provided input into the writing the paper and performed the editing.
Supported by Japan Agency for Medical Research and Development (AMED), No. JP20ak0101093.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Shihori Tanabe, PhD, Senior Research Fellow, Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki 210-9501, Japan.
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: March 29, 2021
Revised: April 9, 2021
Accepted: June 4, 2021
Article in press: June 4, 2021
Published online: June 28, 2021

Artificial intelligence (AI) applications are growing in medicine. It is important to understand the current state of the AI applications prior to utilizing in disease research and treatment. In this review, AI application in the diagnosis and treatment of gastrointestinal diseases are studied and summarized. In most cases, AI studies had large amounts of data, including images, to learn to distinguish disease characteristics according to a human’s perspectives. The detailed pros and cons of utilizing AI approaches should be investigated in advance to ensure the safe application of AI in medicine. Evidence suggests that the collaborative usage of AI in both diagnosis and treatment of diseases will increase the precision and effectiveness of medicine. Recent progress in genome technology such as genome editing provides a specific example where AI has revealed the diagnostic and therapeutic possibilities of RNA detection and targeting.

Keywords: Artificial intelligence, Gastrointestinal disease, RNA, Therapeutic application, Inflammatory diseases

Core Tip: The application of artificial intelligence (AI) in the diagnosis and treatment of disease is a promising approach in medicine. The application of AI approaches in gastrointestinal diseases is summarized and reviewed. AI holds great promise in medicine, but to safely and efficiently apply AI in medicine, the advantages and limitations should first be carefully considered.